Personalis Advances ctDNA Cancer Monitoring with AI Platform
Fremont, California | April 13, 2026 Personalis, Inc. has unveiled new data showcasing its ultrasensitive ctDNA-based cancer monitoring platform,...
ctDNA
Advertisement
Allogene Therapeutics Reports Strong ALPHA3 Trial Data
South San Francisco, California | April 13, 2026 Allogene Therapeutics has announced encouraging interim results from its pivotal Phase...
Blood Test Tracks Immunotherapy Response in Solid Tumors
FOSTER CITY, Calif., March 3, 2026 Adela, Inc. has announced the publication of new clinical validation data in npj...
Natera Validates Tissue-Free MRD Test in Colorectal Cancer
Austin, Texas, January 21, 2026 — Natera, a global leader in cell-free DNA and precision medicine, announced the peer-reviewed...
Guardant Unveils New Multiomic Liquid Biopsy Insights at SABCS 2025
PALO ALTO, CA — December 5, 2025 — Guardant Health announced it will present 14 abstracts at the 2025...
Advertisements
Foresight Diagnostics Demonstrates Ultrasensitive MRD Detection in Early-Stage Lung Cancer at IASLC 2025
Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection, presented new clinical performance data on its Foresight...
Advertisement
